Gkini Maria-Angeliki, Nakamura Mio, Alexis Andrew F, Londoño-Garcia Angela, van de Kerkhof Peter C M, Doss Nejib, Griffiths Christopher E M, Kaufman Bridget, Kleyn Christine E, Lebwohl Mark, Redfern Jan S, Takeshita Junko, Rajagopalan Murlidhar, El Sayed Mahira H
Department of Dermatology, Royal London Hospital,Barts Health NHS Trust, London, UK.
Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
Int J Dermatol. 2025 Apr;64(4):667-677. doi: 10.1111/ijd.17651. Epub 2025 Jan 31.
Variations in epidemiology, pathophysiology, genetics, clinical presentation, management, quality of life (QoL) impact, and access to care and research exist globally across the spectrum of individuals with psoriasis. This article aims to provide an evidence-based update on the characteristics of psoriasis in individuals with skin of color (SOC), a population in which psoriasis data have historically been limited. A literature search was conducted from January 2018 until August 2023 in Pubmed/MEDLINE/Cochrane Library and identified studies with I-III level of evidence using Oxford Centre for Evidence-Based Medicine recommendations. Multiple factors (including biological and non-biological) contribute to differences in clinical features and therapeutic nuances in patient populations with SOC. The prevalence of plaque psoriasis is lower in people with SOC but tends to be more severe. People with SOC are less likely to receive biologic treatment. Although the QoL impact of psoriasis is worse in populations with SOC than in White populations, more research is needed to elucidate variations in presentation and impact across diverse populations. An important limitation of this study is that ethnicity, race, and SOC have not been defined universally or used consistently in the literature. Available evidence provides limited information on populations with SOC outside North America, which limits generalizability across global populations. Furthering our understanding of psoriasis in individuals with SOC is crucial to improving patient care outcomes for diverse patient populations worldwide.
在全球范围内，银屑病患者群体在流行病学、病理生理学、遗传学、临床表现、治疗、生活质量影响以及获得医疗和研究资源等方面存在差异。本文旨在基于证据，更新关于有色人种皮肤（SOC）银屑病患者特征的信息，历史上该人群的银屑病数据有限。于2018年1月至2023年8月在Pubmed/MEDLINE/考克兰图书馆进行文献检索，并根据牛津循证医学中心的建议，纳入具有I-III级证据水平的研究。多种因素（包括生物学和非生物学因素）导致了SOC患者群体临床特征和治疗细微差异。斑块状银屑病在SOC人群中的患病率较低，但病情往往更严重。SOC人群接受生物治疗的可能性较小。尽管银屑病对SOC人群生活质量的影响比白人人群更严重，但仍需要更多研究来阐明不同人群中临床表现和影响的差异。本研究的一个重要局限性在于，文献中尚未对种族、民族和SOC进行统一界定或一致使用。现有证据提供的关于北美以外SOC人群的信息有限，这限制了研究结果在全球人群中的普遍适用性。进一步了解SOC人群的银屑病对于改善全球不同患者群体的医疗护理结局至关重要。
